2 terminated, 1 active not recruiting, 1 recruiting. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow FTD: new trials by email Literature Review of FTD trials Research Report on FTD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Recruiting | AviadoBio Ltd | 18 | 2023-08-30 | 2026-08-13 |
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes PBFT02 - Frontotemporal Dementia, FTD | Phase 1 / Phase 2 | Active not recruiting | Passage Bio, Inc. | 30 | 2021-09-14 | 2026-05-15 |
| Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) WVE-004, Placebo - ALS, FTD | Phase 1 / Phase 2 | Terminated | Wave Life Sciences USA, Inc. | 35 | 2021-06-28 | 2023-10-23 |
Frontotemporal Dementia (3) · Aphasia, Primary Progressive (2) · Dementia (2) · Pick Disease of the Brain (2) · Frontotemporal Dementia With Motor Neuron Disease (1) · Psychomotor Agitation (1)
Brain Diseases (3) · Central Nervous System Diseases (3) · Frontotemporal Lobar Degeneration (3) · Mental Disorders (3) · Metabolic Diseases (3) · Nervous System Diseases (3) · Neurocognitive Disorders (3) · Neurodegenerative Diseases (3) · Nutritional and Metabolic Diseases (3) · Proteostasis Deficiencies (3) · TDP-43 Proteinopathies (3) · Aphasia (2) · Communication Disorders (2) · Language Disorders (2) · Neurobehavioral Manifestations (2)
nabilone (1)
AviadoBio Ltd (1) · Passage Bio, Inc. (1) · Simon Ducharme, MD (1) · Wave Life Sciences USA, Inc. (1)
Canada (4) · Australia (2) · Belgium (2) · Netherlands (2) · Sweden (2) · United Kingdom (2) · United States (2) · Brazil (1) · Ireland (1) · Italy (1) · New Zealand (1) · Poland (1) · Portugal (1) · Spain (1)
Will Chou, MD (1)
2023 (1)